PCSK9 inhibitors: How do they work?
PCSK9: Outcomes and trials in clinical perspective
This video is part of an educational series of four lectures focussed on PCSK9: Outcomes and trials in clinical perspective. In this module, prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.
Video navigation menu
- Central factors to the physiological control of circulating LDL-C levels 01:01
- Function and life cycle of the cellular LDL receptor 02:48
- PCSK9 and its role in regulation of LDL-R expression 05:18
- Development of PCSK9 monoclonal antibodies and their impact on LDL-R expression 11:33
- How do PCSK9 monoclonal antibodies function in statin-treated individuals? 15:14
This educational video is the second part of a series called "PCSK9: Outcomes and trials in clinical perspective" that are aimed to give cardiologists in secondary care and other healthcare professionals with an interest in treating patients with cardiovascular disease a well-balanced expert view on the current state of the art about the impact of PCSK9 inhibition on lipids and cardiovascular risk
This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Other topics covered in this series
Other lectures part of this educational series are:
- Identifying patients for PCSK9 therapy - Prof. Kees Hovingh, MD, Amsterdam University Medical Center , The Netherlands
- Landmark trials with PCSK9 inhibitors - Prof. Gabriel Steg, MD, Hôpital Bichat, Paris, France
- Guidelines and the role of non-statin therapies for high risk ASCVD patients - Prof. Wouter Jukema, MD, Leiden University Medical Center, The Netherlands
John Chapman is Research Professor at the Pierre and Marie Curie University, and Director Emeritus of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpêtrière University Hospital in Paris, France.
This course is applied for online CME accreditation at EBAC (European Board for Accreitation in Cardiology). Once accredited the CME programme will be available in our CME section
This educational series is funded by an unrestricted educational grant provided by Sanofi-Regeneron.